The fragility index (FI), the number of events the statistical significance a result depends on, and the number of patients lost to follow-up are important parameters for interpreting randomised clinical trial results. We evaluated these two parameters in randomised controlled trials in anaesthesiology. For this, we performed a systematic search of the medical literature, seeking articles reporting on anaesthesiology trials with a statistically significant difference in the primary outcome and published in the top five general medicine journals, or the top 15 anaesthesiology journals. We restricted the analysis to trials reporting clinically important primary outcome measures. The search identified 139 articles, 35 published in general medicine journals and 104 in anaesthesiology journals. The median (inter-quartile range) sample size was 150 (70e300) patients. The FI was 4 (2e17) and 3 (2e7), and the number of patients lost to follow-up was 0 (0e18) and 0 (0e6) patients in trials published in general medicine and anaesthesiology journals, respectively. The number of patients lost to follow-up exceeded the FI in 41 and 27% in trials in general medicine journals and anaesthesiology journals, respectively. The FI positively correlated with sample size and number of primary outcome events, and negatively correlated with the reported P-values. The results of this systematic review suggest that statistically significant differences in randomised controlled anaesthesiology trials are regularly fragile, implying that the primary outcome status of patients lost to follow-up could possibly have changed the reported effect.
Editor's key points
The authors examined the fragility index and the number of patients lost to follow-up in randomised controlled trials with major clinical endpoints in anaesthesiology as the primary outcome. Fragility index correlated positively with sample size and number of primary outcome events, and negatively with reported P-values. The number of patients lost to followup exceeded the fragility index in a third of the trials. The authors concluded that statistically significant differences in randomised controlled anaesthesiology trials are regularly fragile, suggesting that primary outcomes in patients lost to follow-up could have influenced findings.
The fragility index (FI) of a randomised controlled trial is the number of patients in the randomisation group with the fewest primary outcome events, whose status would have to change from 'non-event' to 'event' to change a statistically significant difference between treatment arms to a nonsignificant difference. 1 For example, in a trial with an FI of 20, as many as 20 additional patients with an event would be needed to render a statistically significant difference nonsignificant. In contrast, an FI of 1 implies that only one patient changed to the alternative outcome status would change the overall result to a non-significant difference between treatment arms. Thus, the lower the FI the more 'fragile' is the statistical significance finding of a trial. The number of patients lost to follow-up is defined as the number of patients in whom the status of the primary outcome remains unreported no matter the cause. Loss to follow-up could thus cause bias, in particular when the reasons for loss to follow-up are associated with the likelihood of occurrence of the primary outcome. 2 The number of patients lost to follow-up adds to the concept of FI. For instance, in a trial with an FI of 5 in which 10 patients are lost to follow-up, the difference between treatment arms would change to nonsignificant if five or more of these patients would have experienced the primary outcome event. In other words, if the FI is lower than the number of patients lost to follow-up, the statistical significance finding of a trial could be even more 'fragile'. Previous investigations reporting on FI and number of patients lost to follow-up in randomised controlled trials in the domains of general medicine, 1 spinal surgery, 3 intensive care medicine, 4 sports medicine, 5 and recently also cardiology 6 not only show that the FI is frequently low, but also that it is common that the number of patients lost to follow-up exceed the FI. These investigations also show that statistically significant findings are more fragile when trials are smaller in size or have a lower number of primary outcome events. As randomised controlled trials in the field of anaesthesiology are frequently small, and often have small numbers of primary outcome events, we hypothesised that statistically significant findings in these trials suffer from a comparable 'fragility' to those in trials in other domains of medicine. To test this hypothesis, we performed a systematic search of the medical literature, seeking for published randomised controlled anaesthesiology trials to calculate the FI. We compared the FI with the number of patients lost to follow-up, and identified which factors were associated with the FI.
Methods

Search strategy
We performed a systematic search in PubMed/MEDLINE for randomised controlled anaesthesiology trials reporting a statistically significant difference between study arms with regard to the primary outcome. While we did not pre-publish the study protocol, we followed a strict pre-defined plan for both the search and the analysis. We did not perform a formal power calculation. We set the boundaries of the systematic search rather pragmatically. First, we restricted the search to trials reported in the top five general medicine journals or the top 15 anaesthesiology journals, based on their impact factors at the moment we performed the actual search. We assumed that trials reported in these journals would be of high quality, and would contain sufficient information to calculate for example the number of patients lost to follow up. We also restricted the time window to the past 25 yrs (i.e. published since 1991), for the very same reasons. As we updated the search shortly before finalising this paper, we ended up with a time frame of 26 yrs. A complete list of search criteria and journals is presented in the Supplementary material (Table S1 and PubMed full search criteria).
Two reviewers (G.M. and L.B.) independently scanned all articles identified by the search for relevance by reading the title and abstract. For potentially relevant articles, the full text was obtained. In case of disagreement, consensus between the two reviewers was sought. Reference lists of initially selected articles, as well as related reviews and meta-analyses, were searched for additional potentially relevant articles.
Selection of studies
Articles were selected when the following criteria were met: 1) randomised controlled trial in humans, 2) study in the field of perioperative anaesthesiology, performed in operation theatres, with outcomes directly related to perioperative management, 3) reporting a statistically significant difference with regard to the primary outcome, and 4) primary outcome of the study was a 'major clinical endpoint' (see below for definitions). Trials were excluded if: 1) trial design was not a two parallel-arm or a two by two factorial randomised controlled trial (factorial meaning that the effects of two independent interventions were assessed in one single trial); 2) not using 1:1 randomised allocation; and 3) if not reporting on a dichotomic primary outcome, or when it was not possible to dichotomise time-to-event outcomes. In addition, trials using a quasi-or a non-randomised methodology were excluded, as were trials performed outside the operation room. In addition, trials with inaccuracies in the reported number of recruited patients were excluded, which was revealed when the number of patients with a primary outcome event plus the number of patients without a primary outcome event plus the number of patients lost to follow-up did not match the reported number of recruited patients, as well as trials stopped before reaching full recruitment because of safety concerns about the intervention tested.
As mentioned above, we restricted the analysis to trials that used a primary outcome measure that occurred in the intra-or postoperative phase and could be considered to be clinically important and relevant (i.e. a 'major clinical outcome') 7, 8 (see Supplementary Table S2 ). The following outcome measures were included: mortality; delirium or cognitive dysfunction; perioperative myocardial ischemia or arrhythmia or hemodynamic instability; perioperative pulmonary complications; venous thrombosis; acute kidney injury or acute renal failure; blood transfusion; postoperative residual curarization; failed intubation; epidural or spinal anaesthesia complications; surgical wound infection; caesarean section rate or postpartum haemorrhage or eclampsia or preeclampsia or 'haemolysis, elevated liver enzymes and low platelet count' syndrome; or neonatal mortality.
Data extraction
The extracted data included journal name, publication year, number of participating centres, method of blinding, the primary outcome, the assumed effect size used for the power calculation and the sample size based on the power calculation (if reported), the number of patients randomised per randomisation group, the number of patients who experienced the primary endpoint per randomisation group, the level of statistical significance, the number of patients lost to follow-up with regard to the primary outcome, and finally, the observed effect size.
Fragility index calculation
The FI was calculated as reported previously. 1 In short, using 2Â2 contingency tables the P-value was recalculated using a two-sided Fisher exact test. If a statistical finding changed from significant to non-significant by switching to this test, the FI for that trial was defined as '0'. If not, events were iteratively added to the group with the smallest number of events, while maintaining equal total sample size, until the Fisher exact test P-value became >0.05. The number of events needed to reach such a result was the FI.
Lost to follow-up
The number of patients lost to follow-up was defined as the difference between the number of patients randomised and the number of patients evaluable with regard to the primary outcome (i.e. patients who were reported as patients in whom it was unknown whether the primary outcome occurred were considered as lost to follow-up).
Analysis plan
Continuous variables were reported as medians with their inter-quartile range, with standard deviations or ranges where applicable, and categorical variables as counts and percentages. First, the FI distribution was calculated and plotted, as were the number of patients lost to follow-up, and 'FI minus the number of patients lost to follow-up'. For the latter, in case the 'FI minus the number of patients lost to follow-up' became negative it was scored as '0'. Second, FI and 'FI minus the number of patients lost to follow-up' distributions were plotted for several predefined subgroups: by journal type (general medicine vs anaesthesiology); according to the six main outcomes categories: mortality, neurological, myocardial, pulmonary, vascular, kidney, and per sample size (dichotomised by using the median); by number of events (dichotomised by using the median); by assumed effect size (categorised as 'not reported', or 'reported' and then dichotomised by using the median); and by observed effect size (dichotomised by using the median). Finally, we determined which variables correlated with the FI and with 'FI minus the number of patients lost to follow-up' using Spearman's correlation coefficient for continuous variables and Point-Biserial correlation coefficient for dichotomous variables. The variables included: journal impact factor; actual sample size; number of primary outcome events; reported P-value; and the suggested and observed effect size.
Stata version 13 (StataCorp™, College Station, TX, USA) and MATLAB (Mathworks™, Natick, MA, USA) were used for all analyses; two-sided statistical significance was set at a P-value <0.05.
Results
Search results
The initial search identified 13 798 articles, of which 225 were eligible after applying the inclusion criteria. Next, 86 articles were excluded for reasons shown in Figure 1 , yielding 139 articles for the final analysis. Of these, 35 were published in general medicine journals and 104 in anaesthesiology journals. Trial characteristics are shown in Table 1 and  Supplementary Table S3 .
Fragility index and the number of patients lost to follow-up Distribution of FI, losses to follow-up and 'FI minus the number of patients lost to follow-up' distribution are shown in Figure 2 . Overall, in 17/139 (12%) trials, the statistical finding changed from significant to non-significant by using a twosided Fisher exact test; these trials thus had an FI of '0'. The overall FI was 3 (2e8). In 62/139 (44%) trials patients were lost to follow-up, and in 56 (90%) of these, the number of patients lost to follow-up exceeded the FI. 'FI minus the number of patients lost to follow-up' was 2 (0e5), with 41% of all trials having an 'FI minus the number of patients lost to follow-up' of zero.
Subgroups
The FI and 'FI minus the number of patients lost to follow-up' by trial characteristics are shown in Figure 3 . The FI was higher in trials published in general medicine journals compared with anaesthesiology journals, although this difference did not reach statistical significance (P¼0.094). The FI was higher in larger trials (P<0.001), and in trials with a higher number of outcome events (P<0.001). The FI was higher in trials with a lower assumed effect size (P¼0.013), but was not different between trials with a lower vs a higher observed effect size (P¼0.53). The 'FI minus the number of patients lost to followup' was lower in trials with lower observed effect size (P¼0.0072). No other statistically significant difference was found between the 'FI minus the number of patients lost to follow-up' and trial characteristics.
Correlations
There was a positive correlation between FI and the trial sample size, and between FI and the number of primary outcome events in a trial; a negative correlation was found between FI and the reported P-value. There was a positive correlation between 'FI minus the number of patients lost to follow-up' and the number of events in a trial; a negative correlation was found between 'FI minus the number of patients lost to follow-up' and reported P-values (Table 2 and  Supplementary Table S4 and Figs S1e3).
Discussion
The results of this systematic review can be summarised as follows; 1) the FI of randomised controlled anaesthesiology trials is often low, and 2) numbers of patients lost to follow-up with regard to the primary endpoint frequently exceed the FI. In addition, 3) the FI increases with a larger sample size and higher numbers of primary events, and 4) with lower P-values.
Our investigation has several strengths. 1) By using a systematic and strict approach we were not only able to identify all anaesthesiology trials published in a predefined selection of journals, but also to restrict the analysis to those trials that were reported to have a statistically significant difference with respect to its primary endpoint. 2) Our investigation included anaesthesiology trials performed over a long period of time. 3) Most trials used clinically relevant endpoints. Therefore, the findings of this systematic review can be considered representative for research within the domain of anaesthesiology. Moreover, it provides a comprehensive assessment of the robustness of evidence for benefit, or absence thereof, of frequently performed interventions by anaesthesiologists.
When calculating the FI, we explicitly focused on the primary endpoint of each trial. In our opinion, calculation of the FI should only consider the primary endpoint, as clinical trials are designed so that they only have sufficient power to test an effect of a certain intervention or strategy with regard to that specific endpoint. We used the same approach when calculating the number of patients lost to follow-up (i.e. we determined and used this number only when it considered the primary endpoint). In other words, we exclusively tested the robustness of each trial with regard to what it was supposed to test. Of note, the majority of endpoints were outcomes in the intraoperative or early postoperative phase. In this respect, it was also surprising to see that the numbers of patients lost to follow-up with regard to the primary endpoint frequently exceed the FI. Indeed, in trials with a short follow-up time one would expect it to be possible to collect all necessary data, in particular the primary endpoint. The results of this review are largely in line with those from previously published reviews assessing the FI of trials in other medical specialties. One systematic review of trials reported in the top five medical journals showed that one-quarter of the reviewed trials had an FI below 3, and in more than half of those trials, the number of patients lost to follow-up exceeded the FI.
1 Other reviews reported similar findings for trials in spinal surgery 3 and in sports medicine. 5 The present findings are comparable with those of a recent systematic review of trials in the domain of critical care medicine. 4 This may be explained, at least in part, by the fact that anaesthesiology and critical care medicine share many similarities and often research groups have substantial overlap. We expected to find a strong correlation between FI and sample size. In general, the larger a trial is, the more robust its findings will be. This could also be the reason why we found a strong correlation between FI and the ranking of journals. Indeed, papers accepted in higher impact journals usually have larger sample sizes and also larger numbers of events. Most trials included in the present review, though, were small. To mitigate its tendency to have a different meaning in smallvs large-sized trials, 9 it has been suggested that the FI should changing the numbers of events). In case 'fragility index minus the number of patients lost to follow-up' became negative, it was defined to be '0' Visualisation of distributions is truncated to 30 to improve readability. The symbols and whiskers above the bars represent medians and inter-quartile range. be corrected for the sample size of a trial. 10 This approach, however, decreases the easiness and intuitiveness of an 'absolute' FI. We prefer to use the absolute FI, as it corresponds directly to the exact number of patients that would have changed the results of a trial, which is easy to interpret. Also, the absolute FI can be more easily compared with the number of patients lost to follow-up. Furthermore, the potential bias towards a higher FI value with larger trials is somewhat lessened by the fact that these studies are more prone to have sample losses. A low FI does not necessarily mean that a trial is of less value. However, when the number of patients lost to follow-up exceeds the FI, we need to be more cautious, as the true effect of the intervention tested could be hidden in patients in whom it was impossible to score the primary outcome. Exactly this is what trialists may want to hold in mind when planning a new trial. 11 When the risk of loss to follow-up is high, either trialists should choose an outcome that is at a lower risk of loss to follow-up, or they should plan to make the trial so large that even when there is substantial loss to follow-up, patients lost will not exceed the FI. Typically, to determine if a difference or a change in a chosen outcome between two or more study groups is 'statistically significant', investigators usually set the P-value at 0.05, 8 and 95% confidence intervals (CIs) are used to have an estimate of the effect size. 20 However, and as recognised before, the widespread use of 'statistical significance', generally interpreted as a P-value <0.05 as a license for making the claim of a scientific finding, could be misleading. While the FI is a simple and foremost intuitive tool designed to add information to Pvalues and CIs, it is certainly not meant to replace these important numbers. Indeed, the concept of FI should not be overstated. 1) Like P-values, the FI should not be interpreted as a measure of an effect.
2) It could very well be argued that the FI is nothing more than a proxy of the P-value. 21 Higher FIs for a given effect can be obtained by simply increasing the sample size, but this may not always be possible or achievable. In addition to the argument that the FI should always be coupled with other statistical summaries from the study, however, we would like to stress that it should be coupled with the number of patients lost to follow-up. While we must be cautious to rank order the robustness of the statistically significant findings of a trial solely on the FI, we may question the robustness if the number of patients lost to follow-up exceeds the FI. This review has several limitations. First, we restricted the analysis to trials with a statistically significant difference with respect to what we ourselves considered a major clinical endpoint. Our choices concerning what should be seen as 'major', though, could be questioned, in particular because not all of them can be considered patient-centred endpoints. Nevertheless, they are all major endpoints, and have been considered important guides to perioperative anaesthesia management.
7 Also, we choose to limit the search to the current top five general medicine journals and top 15 anaesthesiology journals: this restriction can be seen as arbitrary, as there is no consensus on the boundaries of fragility research in the current literature and journal ranking may vary over time, but this approach could have caused us missing relevant anaesthesiology trials. Notably, as the FI can only be calculated for trials that have a statistically significant difference, several anaesthesiology trials may seem to have been missed. However, many trials were excluded, as they did not show a statistically significant difference with regard to the primary endpoint. Also, we consider only the overall loss to follow-up (i.e. the total number of patients lost to follow in a trial and not the number of patients lost to follow-up per treatment arm in a trial). While this approach has a downside, it was not always possible to determine the exact number per arm of the trial.
In conclusion, the statistically significant difference in randomised controlled anaesthesiology trials is often fragile, and in many trials' outcome status of patients lost to follow-up could have changed the statistical results. By considering the several aspects that influence FI, and by balancing FI with the risk of loss to follow-up, trialists could further improve trials' design. Declarations of interest C.L.E. received payment for educational talks and scientific conferences from Merck Sharp & Dohme (MSD) and has no conflict of interests related to the present work. C.L. Errando received payment for educational talks and scientific conferences from Merck Sharp & Dohme while completing this manuscript although not related to it in any form.
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